No action required for investors unless they wish to change a prior vote. The correction does not affect the substance of any proposals.
NRXP drugs
NRXP drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Feb 25 $1.91entry
- T+1 · 9mo ago +1.05%α +1.59% · $1.93
- T+5 · 9mo ago −2.09%α −0.99% · $1.87
- T+20 · 8mo ago +26.18%α +31.41% · $2.41
- T+60 · 6mo ago +55.50%α +48.55% · $2.97
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
NRx Pharmaceuticals, Inc. filed a supplement to its definitive proxy statement for its 2026 annual meeting, correcting the numbering of proposals on the proxy card and cover letter. The meeting will address director elections, executive compensation, an incentive plan amendment, and auditor ratification. The filing is routine and administrative, with no material financial or strategic changes.
Key Facts
- Filed a supplement to correct proposal numbering on the proxy card and cover letter for the 2026 annual meeting.
- Proposal 2 (executive compensation) was corrected to Proposal 4.
- Proposal 3 (incentive plan amendment) was corrected to Proposal 2.
- Proposal 4 (auditor ratification) was corrected to Proposal 3.
- All other information in the proxy statement remains unchanged.
- The board recommends voting 'For' on all proposals.
Financial Impact
No financial impact. This is a clerical correction to document numbering.
Risk Factors
- None. This is a routine administrative filing with no material risks.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001437749-26-005362 |
| Document: 0001437749-26-005362-index-headers.html | 0001437749-26-005362 |
| Document: 0001437749-26-005362-index.html | 0001437749-26-005362 |
| Document: 0001437749-26-005362.txt | 0001437749-26-005362 |
Track record
22 reports on NRXP
8 of 13 bullish or bearish reports moved the stock their way by T+5. Best: +70.33% at T+60 after the Mar 30, 2026 report. 10 of 13 went positive at some point.
Filters
- Nov 5, 202611d ago DEFA14A Neutral 3/10 Entry $2.38 to $2.19 Now $2.15 −9.66% ▼ −7.98% −10.58% vs SPY
- Nov 5, 202611d ago DEF 14A Neutral 4/10 Entry $2.38 to $2.19 Now $2.15 −9.66% ▼ −7.98% −10.58% vs SPY
- Nov 2, 202614d ago 8-K Bullish 6/10 Entry $2.17 to $2.38 Now $2.15 −0.92% ▲ +9.68% +9.60% vs SPY
- Oct 30, 202617d ago Press Release Bullish 7/10 Entry $2.27 to $2.38 Now $2.15 −5.29% ▲ +4.85% +7.55% vs SPY
- Oct 16, 20264w ago 8-K Neutral 2/10 Entry $2.63 to $2.52 Now $2.15 −18.25% ▼ −4.18% −4.04% vs SPY
- Oct 5, 20266w ago 8-K Bullish 6/10 Entry $2.94 to $2.70 Now $2.15 −26.87% ▼ −8.16% −8.02% vs SPY
- Sep 15, 20268w ago 8-K Bullish 5/10 Entry $3.35 to $3.16 Now $2.15 −35.82% ▼ −5.67% −8.24% vs SPY
- Sep 14, 20269w ago 8-K Neutral 2/10 Entry $3.49 to $3.29 Now $2.15 −38.40% ▼ −5.73% −5.84% vs SPY
- Aug 17, 202613w ago 8-K Bullish 7/10 Entry $3.43 to $3.45 Now $2.15 −37.32% ▲ +0.58% +1.77% vs SPY
- Aug 17, 202613w ago Press Release Neutral 1/10 Entry $3.43 Now $2.15 −37.32% No price data
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers